Home › Triple-Negative Breast Cancer › Nevada
Triple-Negative Breast Cancer clinical trials in Nevada
6 studies for Triple-Negative Breast Cancer are looking for participants at sites in Nevada.
Cities in Nevada
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Optum Care Cancer Center ( Site 9535), Las Vegas
- Comprehensive Cancer Centers of Nevada - Peak ( Site 0047), Las Vegas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Comprehensive Cancer Centers of Nevada ( Site 0015), Las Vegas
- Renown Regional Medical Center ( Site 0005), Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Optum Care Cancer Center ( Site 0050), Las Vegas
- Renown Regional Medical Center ( Site 0041), Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Specialist of Reno, Reno
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07029399A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.